Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology.

Andrés-Benito P, Fernández-Dueñas V, Carmona M, Escobar LA, Torrejón-Escribano B, Aso E, Ciruela F, Ferrer I.

Neuropathol Appl Neurobiol. 2017 Jan 24. doi: 10.1111/nan.12386. [Epub ahead of print]

PMID:
28117912
2.

Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model.

Aso E, Andrés-Benito P, Ferrer I.

J Alzheimers Dis. 2016 Oct 4;54(3):903-912.

PMID:
27567873
3.

An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.

Lachén-Montes M, González-Morales A, de Morentin XM, Pérez-Valderrama E, Ausín K, Zelaya MV, Serna A, Aso E, Ferrer I, Fernández-Irigoyen J, Santamaría E.

J Proteomics. 2016 Oct 4;148:149-58. doi: 10.1016/j.jprot.2016.07.032.

PMID:
27498392
4.

FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau.

López-González I, Palmeira A, Aso E, Carmona M, Fernandez L, Ferrer I.

J Alzheimers Dis. 2016 Sep 6;54(2):471-5. doi: 10.3233/JAD-160274.

PMID:
27497476
5.

Novel Self-Assembling Amino Acid-Derived Block Copolymer with Changeable Polymer Backbone Structure.

Koga T, Aso E, Higashi N.

Langmuir. 2016 Nov 29;32(47):12378-12386.

PMID:
27340892
6.

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.

Aso E, Ferrer I.

Front Neurosci. 2016 May 31;10:243. doi: 10.3389/fnins.2016.00243. Review.

7.

Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.

Aso E, Andrés-Benito P, Carmona M, Maldonado R, Ferrer I.

J Alzheimers Dis. 2016;51(2):489-500. doi: 10.3233/JAD-150913.

PMID:
26890764
8.

Fibrinogen-Derived γ377-395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice.

Aso E, Serrano AL, Muñoz-Cánoves P, Ferrer I.

J Alzheimers Dis. 2015;47(2):403-12. doi: 10.3233/JAD-142928.

PMID:
26401562
9.

Neuroinflammatory Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of Frontotemporal Lobar Degeneration-Tau.

López-González I, Aso E, Carmona M, Armand-Ugon M, Blanco R, Naudí A, Cabré R, Portero-Otin M, Pamplona R, Ferrer I.

J Neuropathol Exp Neurol. 2015 Oct;74(10):975-99. doi: 10.1097/NEN.0000000000000241.

PMID:
26360374
10.

Complex Inflammation mRNA-Related Response in ALS Is Region Dependent.

Berjaoui S, Povedano M, Garcia-Esparcia P, Carmona M, Aso E, Ferrer I.

Neural Plast. 2015;2015:573784. doi: 10.1155/2015/573784.

11.

Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.

Sola I, Aso E, Frattini D, López-González I, Espargaró A, Sabaté R, Di Pietro O, Luque FJ, Clos MV, Ferrer I, Muñoz-Torrero D.

J Med Chem. 2015 Aug 13;58(15):6018-32. doi: 10.1021/acs.jmedchem.5b00624.

PMID:
26181606
12.

Memory Improvement in the AβPP/PS1 Mouse Model of Familial Alzheimer’s Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes.

Armand-Ugón M, Aso E, Moreno J, Riera-Codina M, Sánchez A, Vegas E, Ferrer I.

J Alzheimers Dis. 2015;45(2):407-21. doi: 10.3233/JAD-150002.

PMID:
25790933
13.

Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species.

López-González I, Schlüter A, Aso E, Garcia-Esparcia P, Ansoleaga B, LLorens F, Carmona M, Moreno J, Fuso A, Portero-Otin M, Pamplona R, Pujol A, Ferrer I.

J Neuropathol Exp Neurol. 2015 Apr;74(4):319-44. doi: 10.1097/NEN.0000000000000176.

PMID:
25756590
14.

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.

Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I.

J Alzheimers Dis. 2015;43(3):977-91. doi: 10.3233/JAD-141014.

PMID:
25125475
15.

Baclofen and 2-hydroxysaclofen modify acute hypolocomotive and antinociceptive effects of nicotine.

Varani AP, Aso E, Maldonado R, Balerio GN.

Eur J Pharmacol. 2014 Sep 5;738:200-5. doi: 10.1016/j.ejphar.2014.05.039.

PMID:
24886886
16.

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.

Aso E, Ferrer I.

Front Pharmacol. 2014 Mar 5;5:37. doi: 10.3389/fphar.2014.00037. Review.

17.

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Varani AP, Aso E, Moutinho LM, Maldonado R, Balerio GN.

Psychopharmacology (Berl). 2014 Aug;231(15):3031-40. doi: 10.1007/s00213-014-3469-6.

PMID:
24553576
18.

Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease.

Sanchez-Mut JV, Aso E, Heyn H, Matsuda T, Bock C, Ferrer I, Esteller M.

Hippocampus. 2014 Apr;24(4):363-8. doi: 10.1002/hipo.22245.

19.

Genetically modified mice as tools to understand the neurobiological substrates of depression.

Robledo P, Martín-García E, Aso E, Maldonado R.

Curr Pharm Des. 2014;20(23):3718-37. Review.

PMID:
24180392
20.

Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009.

Nakamura Y, Aso E, Yashiro M, Tsuboi S, Kojo T, Aoyama Y, Kotani K, Uehara R, Yanagawa H.

J Epidemiol. 2013;23(6):429-34.

Items per page

Supplemental Content

Support Center